12:00 AM
 | 
Jan 17, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Neovastat (AE-941): Phase III trial update

Aeterna Laboratories Inc. (TSE:AEL), Quebec City, Quebec
Product: Neovastat (AE-941)
Business: Cancer
Therapeutic category: Angiogenesis
Target: Matrix metalloproteinases and VEGF
Description: Oral blocker...

Read the full 102 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >